Text focuses on diagnosing infections in immunocompromise...(providers' libraries and contribute posi...)
Navigation Links
Text focuses on diagnosing infections in immunocompromised patients
Date:10/9/2008
providers' libraries and contribute positively to the care of these increasingly complex patients. By sharing this information and working effectively together with a patient-focused approach, it is our hope that we can help face the challenges of providing optimal diagnostics services to the immunocompromised patients in our care," says Hayden.
'/>"/>
| Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology Source:Eurekalert |
Related biology news :
1. New lab manual focuses on essential methods for purifying and characterizing proteins
2. Project focuses on production of hydrogen from bacteria and sunlight
3. Publication offers labs consensus recommendations for diagnosing parasitic diseases
4. Hidden infections crucial to understanding, controlling disease outbreaks
5. Antimicrobial sutures reduce infections in brain shunt surgery, study finds
6. CMV infections affect more than just patients with compromised immune systems, researchers find
7. Analysis of RNA role in spreading disease advances study of damaging plant infections
8. Bacterial infections in premature babies more common than previously realized
9. New drug targets may fight tuberculosis and other bacterial infections in novel way
10. Bacteria that cause urinary tract infections invade bladder cells
11. Best treatment identified to reduce deadly Staph infections
Post Your Comments:
Breaking Biology News(10 mins):Studying hair of ancient Peruvians answers questions about stress 2Study confirms association between tobacco smoke and behavioral problems in children 2CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2UT Southwestern physicians bust myths about insulin 54134 1UT Southwestern physicians bust myths about insulin 54134 2Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock 13480 1Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock 13480 2Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 1Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 2Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 3Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 4Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 5Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 6
Other Biology News:Telemedicine robots help improve health 2Air travel and flu: Post-9/11 restrictions delayed start of season 2
Breaking Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 2BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 3
[0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease[0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products[0] BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes
Other Biology Technology:Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 3Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 4
Biology Products:
Mouse Anti-p14 ARF / p16Beta Ab-2 Mouse Monoclonal Antibody, Unconjugated, Clone 14P02 from Lab Vision10 x ReddyRun Gel Loading Buffer from ABgeneAnti-Acetylcholinesterase Monoclonal Antibody, Unconjugated, Clone AE-2 from CHEMICONMouse Anti-IgG2 (Fc, gamma-2 epitope) Monoclonal Antibody, Unconjugated, Clone 52G1 from Meridian Life Science, Inc.
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |